leisure time -WSS

leisure time

author：comprehensive 2025-09-06 03:26:24 - browse：53

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Travis Kelce and the trap of celebrity vaccine endorsements

WSS

Texas Department of Public Safety speaks out on migrant abuse allegations

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Judge rejects Trump's request to move Stormy Daniels hush

Brain injuries and the importance of a second opinion

Medicare proceeds with plan to claw back hospital funds

Judge rejects Trump's request to move Stormy Daniels hush

hotspot

leisure time

explore

As demand for Covid shots wanes, Moderna seeks its next success

Brain injuries and the importance of a second opinion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Stanford president faces new allegations over 1999 paper

Alkermes shareholders re

Infant mortality in U.S. rose last year for first time in decades: CDC

Cancer drug shortages should be causing more outrage

Infant mortality in U.S. rose last year for first time in decades: CDC

The high cost of giving birth even with insurance

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

entertainment

Kidney transplant patients stopped immunosuppressants in trial

Live blog: Hearing on CRISPR

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

After Sarepta trial failure, Duchenne families brace for more debate

Lung cancer screening guidelines updated for cigarette smokers

Affordable Connectivity Program vital to health care, experts say

leisure time

explore

knowledge

entertainment